Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Target posts modest Q2 beat, same-store sales decline

(Sharecast News) - Shares in retail giant Target slumped early on Wednesday despite posting a modest beat in its second-quarter results, as disciplined cost control and digital growth helped offset continued softness in store traffic and merchandise margins. Target said adjusted earnings per share came in at $2.05, ahead of the $2.03 expected by analysts, while revenues dipped 0.9% year-on-year to $25.2bn as overall sales remained under pressure amid cautious consumer spending.

Same-store sales declined 2.3%, a narrower drop than expected, while digital comparable sales rose 4.3%, driven by over 25% growth in same-day delivery. Non-merchandise revenues jumped 14.2% but operating income fell 17.4% to $934m.

Operating margins slipped to 3.76% and gross margins contracted by 140 basis points to 21.5%, reflecting higher markdowns and elevated supply chain costs

Looking ahead, Target reaffirmed its full-year guidance, forecasting a low-single-digit decline in sales and adjusted earnings per share of $7.50 to $8.00.

The Minneapolis-based retailer also named chief operating officer Michael Fiddelke as its next chief executive, succeeding current CEO Brian Cornell on 1 February 2026. Cornell will then transition into an executive chair role.

As of 1355 BST, Target shares were down 9.82% in pre-market action at $95.01 each.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.